 Connection
Peter Dempsey to Neoplasms
This is a "connection" page, showing publications Peter Dempsey has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.430 |
|
|
|
-
Dempsey PJ. Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. Biochim Biophys Acta Mol Cell Res. 2017 Nov; 1864(11 Pt B):2228-2239.
Score: 0.224
-
Moss ML, Stoeck A, Yan W, Dempsey PJ. ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol. 2008 Feb; 9(1):2-8.
Score: 0.116
-
Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med. 2014 Jun; 3(3):492-9.
Score: 0.044
-
Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009; 15(20):2288-99.
Score: 0.031
-
Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart PM, Gillispie PA, Stoeck A, Wildeboer D, Bartsch JW, Palmisano R, Zhou P. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem. 2007 Dec 07; 282(49):35712-21.
Score: 0.007
-
Sanderson MP, Dempsey PJ, Dunbar AJ. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors. 2006 Jun; 24(2):121-36.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|